RelaÃÃo do antÃgeno prostÃtico especÃfico com hiperplasia prostÃtica benigna e adenocarcinoma prostÃtico em casos de Pernambuco

AUTOR(ES)
DATA DE PUBLICAÇÃO

2004

RESUMO

The prostate cancer is a type of cancer which have the most incidence disease in the male-sex (men), and sighting the failure of researching in the state in Pernambuco and the population of that state, itÂs necessary study the relation of the PSA with the age in cases of benign prostate hyperplasia (BPH) and prostatic adehenocarcinoma, as well as in these cases of histopatological results (between 1996 and 2002) from the file of Integrated Center of Patological Anatomy â Oswald Cruz Universitary Hospital, 37 being of BPH (medium age 70,4 years) and 18 cases of prostatic adhenocarcinoma (medium of 73,4 years). The cases of BPH werw divided in groups by levels of total PSA (PSAt), being 37 cases in P1 (0 = PSAt = 113 ng/mL), 7 in P2 (PSAt = 4 ng/mL), 15 in P3 (4,1 = PSAt = 10 ng/mL), 15 in P4 (PSAt = 10,1 ng/mL), 7 in P5 (PSAt = 4,1 ng/mL) and 30 cases in P6 (PSAt >4,1 ng/mL); in accord with the age by groups: 37 cases in I1 (of 55 to 89 years), 9 in I2 ( = 65 years) and 28 in I3 ( = 65 years). The cases of prostatic adhenocarcinoma were divided in groups in accord with the total PSA, being 18 of these cases in P1, 12 in P2, and 6 in P3; in accord to the age by groups: 18 cases in I1, 4 in I2 and 14 in I3; in accord to the Gleason score by groups: 18 cases in G1 (2 to 10), 12 in G2 (2 to 6) and 6 in G3 (7 to 10). For statistic analysis were used the Chi-Square test, the exact test by Fisher, the Spearman and Pearson test. Values of P <0,05 were considered statiscally signficant. In the cases of BPH there werenÂt difference between proportions: age (groups I2 e I3) versus PSA (groups P2, P3, P4) (p=0,550), age (groups I2 e I3) versus PSA (groups P5 e P6) (p=0,656), this can be due to the minimum age in ours cases be of 55 years; there were a significant correlation between: age (groups I1) versus PSA (groups P1) (p=0,027). In the cases of prostatic adhenocarcinoma there werenÂt difference between the proportions: age (groups I2 e I3) versus PSA (groups P3 e P4) (p=1,000); The Gleason score (groups G2 e G3) versus PSA (groups P3 e P4)(p= 0,615); there werenÂt a significant correlation between: age (I1) versus PSA (P1) (p=0,265) this can be also due to the minimum age of ours cases studied; and age (I1) versus Gleason score (G1) (p=0,925); there were a significant correlation between: Gleason score (G1) versus PSA (P1) (p=0,016). Our results permit us conclude the PSA can not be used like accurate marker to the prostate cancer diagnosis, neither can not be used for a differential diagnosis from this with the BPH

ASSUNTO(S)

hiperplasia prostÃtica benigna escore de gleason antÃgeno prostÃtico especÃfico anatomia patologica e patologia clinica antigen prostatic especific psa hpb psa prostatic cancer gleason score gleason cÃncer prostÃtico benign prostatic hyperplasia bph gleason

ACESSO AO ARTIGO

Documentos Relacionados